T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates

[1]  Arvind H. Patel,et al.  Monoclonal anti‐envelope antibody AP33 protects humanized mice against a patient‐derived hepatitis C virus challenge , 2016, Hepatology.

[2]  Saumitra Das,et al.  Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy. , 2016, Vaccine.

[3]  R. Ray,et al.  Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine‐induced neutralizing activity , 2015, Hepatology.

[4]  C. Walker,et al.  Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? , 2015, Current opinion in immunology.

[5]  S. Zolla-Pazner,et al.  An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates , 2015, Journal of Virology.

[6]  S. Self,et al.  Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates , 2015, Journal of Virology.

[7]  M. Hellard,et al.  The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments , 2015, BMC Medicine.

[8]  A. Boonstra,et al.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. , 2015, World journal of hepatology.

[9]  M. Diamond,et al.  Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus , 2015, Journal of Virology.

[10]  Mark M. Davis,et al.  A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.

[11]  N. Sardesai,et al.  Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine , 2014, Human vaccines & immunotherapeutics.

[12]  W. Tan,et al.  The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Charles M. Rice,et al.  Completion of the entire hepatitis C virus life-cycle in genetically humanized mice , 2013, Nature.

[14]  S. Draper,et al.  Utilizing poxviral vectored vaccines for antibody induction—Progress and prospects , 2013, Vaccine.

[15]  P. Klenerman,et al.  Ever closer to a prophylactic vaccine for HCV , 2013, Expert opinion on biological therapy.

[16]  T. Baumert,et al.  Hepatitis C virus vaccines--progress and perspectives. , 2013, Microbial pathogenesis.

[17]  S. Draper,et al.  Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets , 2013, Expert review of vaccines.

[18]  J. Excler,et al.  A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults , 2012, PloS one.

[19]  J. Bukh.  Animal models for the study of hepatitis C virus infection and related liver disease. , 2012, Gastroenterology.

[20]  N. Sardesai,et al.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  D. Montefiori,et al.  Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial , 2011, PloS one.

[22]  A. Hill,et al.  CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria , 2011, The Journal of Immunology.

[23]  A. Hill,et al.  Viral vectors as vaccine platforms: deployment in sight. , 2011, Current opinion in immunology.

[24]  H. Dahari,et al.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. , 2010, Gastroenterology.

[25]  A. Osterhaus,et al.  MVA-Based H5N1 Vaccine Affords Cross-Clade Protection in Mice against Influenza A/H5N1 Viruses at Low Doses and after Single Immunization , 2009, PloS one.

[26]  T. Baumert,et al.  Development of hepatitis C virus vaccines: challenges and progress , 2009, Expert review of vaccines.

[27]  B. Bartosch,et al.  Vaccine‐induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD‐1 and chronicity , 2007, Hepatology.

[28]  J. Heeney,et al.  Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. , 2005, The Journal of infectious diseases.

[29]  D. Ho,et al.  Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region , 2005, Journal of Virology.

[30]  W. Britt,et al.  Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus , 2004, Journal of Virology.

[31]  R. Doms,et al.  Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection , 2004, Journal of Virology.

[32]  J. Heeney,et al.  Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response , 2004, Journal of Virology.

[33]  H. McShane,et al.  Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara1 , 2003, The Journal of Immunology.

[34]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[35]  M. Kieny,et al.  Comparative Vaccine Studies in HLA-A2.1-Transgenic Mice Reveal a Clustered Organization of Epitopes Presented in Hepatitis C Virus Natural Infection , 2002, Journal of Virology.

[36]  J. Prieto,et al.  Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. , 2002, Vaccine.

[37]  S. Emerson,et al.  Vaccination of Chimpanzees With Plasmid DNA Encoding the Hepatitis C Virus (HCV) Envelope E2 Protein Modified the Infection After Challenge With Homologous Monoclonal HCV , 2000, Hepatology.

[38]  T. Santantonio,et al.  Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. , 1999, Gastroenterology.

[39]  P. Liljeström,et al.  Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particles , 1999, Journal of Virology.

[40]  A. Weiner,et al.  Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Sugimura,et al.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  N. Sardesai,et al.  Hepatitis C Virus NS3/NS4A DNA Vaccine Induces Multiepitope T Cell Responses in Rhesus Macaques Mimicking Human Immune Responses. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  M. Houghton,et al.  Recurrence of hepatitis C virus after loss of virus specific CD4+ T cell response in acute hepatitis C , 1998 .

[44]  C. Trépo,et al.  PCR detection of HCV RNA among French non-A, non-B hepatitis patients. , 1992, Archives of virology. Supplementum.